Search Results - "Marszalek, Joe"

Subunit Composition of Neurofilaments Specifies Axonal Diameter by Xu, Zuoshang, Marszalek, Joe R., Lee, Michael K., Wong, Philip C., Folmer, Janet, Crawford, Thomas O., Hsieh, Sung-Tsang, Griffin, John W., Cleveland, Don W.

“…Neurofilaments (NFs), which are composed of NF-L, NF-M, and NF-H, are required for the development of normal axonal caliber, a property that in turn is a…”
Get full text

A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma by Vashisht Gopal, Y N, Gammon, Seth, Prasad, Rishika, Knighton, Barbara, Pisaneschi, Federica, Roszik, Jason, Feng, Ningping, Johnson, Sarah, Pramanik, Snigdha, Sudderth, Jessica, Sui, Dawen, Hudgens, Courtney, Fischer, Grant M, Deng, Wanleng, Reuben, Alexandre, Peng, Weiyi, Wang, Jian, McQuade, Jennifer L, Tetzlaff, Michael T, Di Francesco, Maria E, Marszalek, Joe, Piwnica-Worms, David, DeBerardinis, Ralph J, Davies, Michael A

“…The purpose of this study is to determine if inhibition of mitochondrial oxidative phosphorylation (OxPhos) is an effective strategy against MAPK pathway…”
Get full text

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy by White, Michael, Vellano, Christopher P., Andrews, Miles Cameron, Witt, Russell G., Chelvanambi, Manoj, McQuade, Jennifer Leigh, Burton, Elizabeth M., Chu, Yanshuo, Lastrapes, Matthew J, Lau, Mike R., Banerjee, Hiya, Lazar, Alexander J., Davies, Michael A., Woodman, Scott Eric, Wang, Linghua, Moran, Amy E., Long, Georgina V., Heffernan, Timothy, Marszalek, Joe R., Wargo, Jennifer Ann

“…9523 Background: Treatment with BRAF+/-MEK inhibition (BRAF+/-MEKi) has revolutionized treatment in melanoma and other cancers, but resistance is common and…”
Get full text

Abstract 317: Vecabrutinib inhibits C481 mutated Bruton's tyrosine kinase and its downstream signaling in vitro by Aslan, Burcu, Mahendra, Mikhila, Peoples, Michael D, Marszalek, Joe R., Vellano, Christopher P, Zheng, Xiaofeng, Wang, Jing, Taverna, Pietro, Gandhi, Varsha

“…Inhibition of Bruton’s Tyrosine Kinase (BTK) by ibrutinib, an irreversible inhibitor, has dramatically improved the outcomes in both previously treated and…”
Get full text

Abstract 3688: Exploring metabolic vulnerabilities of metastatic prostate cancer to bone by Mossa, Federica, Robesti, Daniele, Vellano, Christopher, Titus, Mark, Marszalek, Joe, Frigo, Daniel, Logothetis, Christopher, Gujral, Taranjit, Dondossola, Eleonora

“…Currently, limited knowledge is available on subtype-specific metabolic features and their implications for treatment. Here, we investigated the metabolic…”
Get full text

Abstract 2831: Collateral lethality: A new target for personalized oncology by Lin, Yu-Hsi, Hammoudi, Naima, Satani, Nikunj, Ackroyd, Jeffrey, Khadka, Sunada, Georgiou, Dimitra, Marszalek, Joe, Sun, Yuting, Protopopova, Marina, Francesco, Maria E. Di, Czako, Barbara, Wang, Alan Y., DePinho, Ronald A., Muller, Florian L.

“…Large-scale genomic profiling efforts, such as The Cancer Genome Atlas (TCGA) have painted an unprecedentedly detailed picture of the genetic alterations that…”
Get full text

Abstract 3229: IACS-16559, a CBP/P300 bromodomain inhibitor for the treatment of specific AML subsets by Zanca, Ciro, Soth, Michael, Gao, Guang, Gay, Jason, Feng, Ningping, Bristow, Christopher, Le, Kang, Xu, Quanyun, Nguyen, Phuong, Jiang, Yongying, Perry, Teresa, Mseeh, Faika, Leonard, Paul, Cross, Jason, Giuliani, Virginia, Marszalek, Joe, Jones, Philip, Heffernan, Tim

“…Block in differentiation and accumulation of undifferentiated blasts are hallmarks of Acute Myeloid Leukemia (AML) and epigenetic processes have been shown to…”
Get full text

Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer by Evans, Kurt, Moulder, Stacy, Yuca, Erkan, Scott, Stephen, Arango, Natalia Paez, Shariati, Maryam, Vellano, Christopher P, Saridogan, Turcin, Zheng, Xiaofeng, Gonzalez-Angulo, Ana Maria, Zhao, Ming, Su, Xiaoping, Tapia, Coya, Chen, Ken, Akcakanat, Argun, Perou, Charles M, Lim, Bora, Tripathy, Debu, Yap, Timothy A, Francesco, Maria E Di, Draetta, Giulio, Jones, Philip, Marszalek, Joe, Meric-Bernstam, Funda

“…There is a pressing need to identify improved therapies for triple negative breast cancers (TNBC) resistant to standard chemotherapy. To identify potential…”
Get full text

Abstract 3837: Passenger deletion of ENO1 as a collateral lethality target in cancer by Lin, Yu-Hsi, Satani, Nikunj, Hammoudi, Naima, Marszalek, Joe, Sun, Yuting, Protopopova, Marina, Di Francesco, Maria E., Czako, Barbara, Wang, Alan, DePinho, Ronald A., Muller, Florian L.

“…Large scale genomic characterization efforts such as TCGA have painted an unprecedentedly detailed picture of the genetic alterations that underlie…”
Get full text

Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy by Meric-Bernstam, Funda, Evans, Kurt, Zheng, Xiaofeng, Su, Xiaoping, Yuca, Erkan, Scott, Stephen, Akcakanat, Argun, Ueno, Naoto, Lim, Bora, Litton, Jennifer, Valero, Vicente, Symmans, Fraser, Hortobagyi, Gabriel, Perou, Charles, Tripathy, Debu, Draetta, Guilio, Marszalek, Joe, Gonzalez-Angulo, Ana Maria, Moulder, Stacy

“…Altered cellular metabolism is a hallmark of cancer. It is increasingly recognized that selected tumors are dependent on oxidative phosphorylation (OXPHOS)…”
Get full text

Abstract A52: Overcoming mitochondrial oxidative phosphorylation-mediated resistance to targeted therapies in melanoma by Yennu-Nanda, Vashisht Gopal, Hu, Zeping, Thiele, Victoria M., Heffernan, Tim, DiFrancesco, Maria, Marszalek, Joe, Deberadinis, Ralph, Davies, Michael A.

“…There is a critical need to understand and overcome resistance to targeted therapy in cancer. While FDA-approved BRAF and MEK inhibitors achieve clinical…”
Get full text

Abstract LB-071: Discovery of an imidazopyridine series of potent human IDO1 inhibitors with robust target engagement in a preclinical tumor model by Petrocchi, Alessia, Reyna, Naphtali J., Mseeh, Faika, Parker, Connor A., Yu, Simon, Xu, Quanyun, Feng, Ningping, Leonard, Paul, Rogers, Norma, Cross, Jason B., Harris, Angela L., Jiang, Yongying, Khor, Tin Oo, Mahendra, Mikhila G., Pang, Jihai, Wu, Qi, Zuniga, Andy M., McAfoos, Timothy, Hamilton, Matthew M., Marszalek, Joe R., Mikule, Keith, Vancutsem, Paul, Wilcoxen, Keith, Tremblay, Martin, Jones, Philip, Lewis, Richard T.

“…Indoleamine 2,3-dioxygenase (IDO1 and IDO2) and tryptophan dioxygenase (TDO) are heme-containing enzymes that mediate the rate limiting step in the oxidative…”
Get full text

Targeting Oxphos Pathway Against Ibrutinib Resistance to Mantle Cell Lymphoma by Liu, Yang, Bell, Taylor, Zhang, Hui, Sun, Yuting, Li, Carrie J, Feng, Ningping, Huang, Shengjian, Guo, Hui, Wang, Jack, Ahmed, Makhdum, Zhang, Victoria, Lam, Laura T, Nomie, Krystle, Zhang, Liang, Di Francesco, Maria E, Marszalek, Joe, Wang, Michael

“…Background: Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy that is initially responsive but ultimately relapses to frontline therapy. Ibrutinib,…”
Get full text

Abstract 4304: Chromosome 3 dosage-loss informs on the unique biology underlying ultra high-risk uveal melanoma by Rose, Johnathon Lynn, Srinivasan, Sanjana, He, Meng, Minelli, Rosalba, Liu, Chiu-Yi, Terranova, Christopher, Gay, Jason, Daniele, Joseph R., Dmitriy, Loza, Peoples, Michael, Soeung, Melinda, Ramamoorthy, Vandhana, Shah, Parth, Soni, Sanjay, Bristow, Christopher, Wang, Fangyang, Lopez, Anastasia, Deckard, Charles, Meyers, Brooke, Perelli, Luigi, Wani, Khalida, Feng, Ningping, Vellano, Christopher P., Marszalek, Joe, Lazar, Alexander J., Futreal, Andrew, Draetta, Giulio F., Woodman, Scott E., Heffernan, Timothy, Genovese, Giannicola, Carugo, Alessandro, Giuliani, Virginia

“…Uveal melanoma (UM) is a rare and lethal tumor characterized by mutually exclusive activating mutations in GNAQ and GNA11, secondary mutations in EIF1AX, SF3B1…”
Get full text

Abstract A39: Pomhex, a cell-permeable high potency enolase inhibitor with utility for collateral lethality treatment of cancer by Lin, Yu-Hsi, Satani, Nikunj, Hammoudi, Naima, Pisaneschi, Federica, Leonard, Paul, Maxwell, David, Peng, Zhenghong, Link, Todd, Gilbert, Lee IV R., Bosajou, Ananth, Sun, Duoli, Marszalek, Joe, Sun, Yuting, McMurray, John S., Mandal, Pijus K., Francesco, Maria E. Di, Czako, Barbara, Wang, Alan, Bornmann, William, DePinho, Ronald A., Muller, Florian

“…Glycolysis inhibition is an active area of investigation for the treatment of cancer. However, few compounds have progressed beyond the cell culture stage. We…”
Get full text

Abstract 4768: Novel peptidic CXCR4 antagonist LY2510924 disrupts the SDF-1α/CXCR4 axis resulting in anti-AML efficacy in vivo by Cho, Byung Sik, Zeng, Zhihong, Mu, Hong, McQueen, Teresa, Protopopova, Marina, Cortes, Jorge, Marszalek, Joe, Peng, Sheng-Bin, Thornton, Donald E., Andreeff, Michael, Konopleva, Marina

“…Disruption of the SDF-1α/CXCR4 axis by CXCR4 inhibitors has been proven to be an attractive investigational therapeutic approach for acute myeloid leukemia…”
Get full text

Abstract 94: Advanced preclinical modeling reveals unique monosomy 3 associated biology in late-stage uveal melanoma by Rose, Johnathon L., Srinivasan, Sanjana, He, Meng, Minelli, Rosalba, Liu, Chiu-Yi, Gay, Jason, Daniele, Joseph R., Peoples, Michael, Soeung, Melinda, Ramamoorthy, Vandhana, Lopez, Anastasia, Deckard, Charles, Meyers, Brooke, Poggetto, Edoardo Del, Zamler, Daniel, Huang, Justin, Perelli, Luigi, Wani, Khalida, Bristow, Christopher, Feng, Ningping, Vellano, Christopher P., Marszalek, Joe, Lazar, Alexander J., Futreal, Andrew, Draetta, Giulio F., Woodman, Scott E., Heffernan, Timothy, Genovese, Giannicola, Carugo, Alessandro, Giuliani, Virginia

“…Uveal melanoma (UM) is a rare and lethal malignancy with very limited therapeutic options characterized by mutually exclusive activating mutations in GNAQ and…”
Get full text

Abstract C183: Pomhex: a cell-permeable high potency Enolase inhibitor with in vivo anti-neoplastic activity by Lin, Yu-Hsi, Marszalek, Joe, Sun, Yuting, Hammoudi, Naima, Leonard, Paul, Maxwell, David, Satani, Nikunj, Zhang, Peng, Link, Todd, Lee, Gilbert, Di Francesco, Maria E., Czako, Barbara, Want, Alan Y., DePinho, Ronald A., Muller, Florian L.

“…Glycolysis inhibition is an active area of investigation in cancer. However, few compounds have progressed beyond the cell culture stage. We have recently…”
Get full text

Pronounced Anti-Leukemia Activity in Vivo of the Novel Peptidic CXCR4 Antagonist LY2510924 As a Single Agent and in Combination with Chemotherapy by Cho, Byung-Sik, Zeng, Zhihong, Mu, Hong, Wang, Zhiqiang, McQueen, Teresa, Protopopova, Marina, Cortes, Jorge E., Marszalek, Joe, Peng, Sheng-Bin, Davis, Richard Eric, Thornton, Donald, Andreeff, Michael, Konopleva, Marina

“…LY2510924 is a novel selective peptidic CXCR4 antagonist that blocks SDF-1α from binding to its receptor. We have demonstrated that LY2510924 at nanomolar…”
Get full text

Increasing Neurofilament Subunit NF-M Expression Reduces Axonal NF-H, Inhibits Radial Growth, and Results in Neurofilamentous Accumulation in Motor Neurons by Wong, Philip C., Marszalek, Joe, Crawford, Thomas O., Xu, Zuoshang, Hsieh, Sung-Tsang, Griffin, John W., Cleveland, Don W.

“…The carboxy-terminal tail domains of neurofilament subunits neurofilament NF-M and NF-H have been postulated to be responsible for the modulation of axonal…”
Get full text